Education
About Us
Working with TipRanks
Follow Us
Replimune Group (REPL)
:REPL
REPL Stock Chart & Stats
$10.45
$0.17(1.56%)
At close: 4:00 PM EST
$10.45
$0.17(1.56%)
Day’s Range― - ―
52-Week Range$2.68 - $17.00
Previous CloseN/A
Volume95.41K
Average Volume (3M)8.26M
Market Cap
$796.95M
Enterprise Value$523.17M
Total Cash (Recent Filing)$403.34M
Total Debt (Recent Filing)$76.33M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Oct 30, 2025EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding78,055,850
10 Day Avg. Volume14,755,960
30 Day Avg. Volume8,259,675
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue355.42
Enterprise Value/Gross Profit-184.93
Enterprise Value/Ebitda-1.94
Forecast
1Y Price Target
$10.00Price Target Upside-4.31% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Increased Approval ProbabilityThe probability of approval for RP1 + Opdivo in anti-PD1 failed melanoma patients has been raised to 85% from the prior 50%.
Market ConfidenceThe analyst has upgraded the stock to 'Buy' with a price target of $12 per share, reflecting confidence in the company's potential.
Regulatory ProgressThe FDA has accepted the resubmission of the Biologics License Application for RP1 + Opdivo for review, indicating progress towards potential approval.
Bears Say
Approval Process ChallengesThere is a prolonged path to approval for RP1, as Replimune will likely have to run another trial to garner approval in the U.S.
Inadequate DataThere is inadequate data to support the statistical assumption of a six-month improvement in the primary endpoint of overall survival.
Trial Design ConcernsThe FDA did not view the IGNYTE trial as an adequate and well-controlled clinical investigation, raising concerns about its effectiveness.
Replimune Group News
REPL FAQ
What was Replimune Group’s price range in the past 12 months?
Replimune Group lowest stock price was $2.68 and its highest was $17.00 in the past 12 months.
What is Replimune Group’s market cap?
Replimune Group’s market cap is $796.95M.
When is Replimune Group’s upcoming earnings report date?
Replimune Group’s upcoming earnings report date is Oct 30, 2025 which is today.
How were Replimune Group’s earnings last quarter?
Currently, no data Available
Is Replimune Group overvalued?
According to Wall Street analysts Replimune Group’s price is currently Overvalued.
Does Replimune Group pay dividends?
Replimune Group does not currently pay dividends.
What is Replimune Group’s EPS estimate?
Replimune Group’s EPS estimate is -0.74.
How many shares outstanding does Replimune Group have?
Replimune Group has 78,055,850 shares outstanding.
What happened to Replimune Group’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Replimune Group?
Currently, no hedge funds are holding shares in REPL
Replimune Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (-4.31% Downside)
$10.00 (-4.31% Downside)
Blogger Sentiment
Bullish
REPL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 37.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $49.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.85%
12-Months-Change
Fundamentals
Return on Equity
-73.44%
Trailing 12-Months
Asset Growth
-12.24%
Trailing 12-Months
Company Description
Replimune Group
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
REPL Stock 12 Month Forecast
Average Price Target
$10.00
▼(-4.31% Downside)
Technical Analysis
Anavex Life Sciences
―
Arcus Biosciences
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
Currently, No data available
---